Loading provider…
Loading provider…
Anatomic Pathology & Clinical Pathology Physician in Fullerton, CA
NPI: 1396037537Primary Practice Location
PROVIDENCE ST. JUDE MEDICAL CENTER
101 E Valencia Mesa Dr, Fullerton, CA
Primary Employer
THE PATHOLOGY GROUP INC
HQ Phone
Get M.D. Mark's Phone NumberMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2013 - 2027

American Board of Pathology
Pathology - Anatomic/Pathology - Clinical

American Board of Pathology
Cytopathology
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Fellowship • Cytopathology
2016 - 2017
Residency • Pathology-Anatomic and Clinical
2011 - 2015
University of Southern California/Los Angeles General Medical Center (USC/LA General) Surgical Pathology
Fellowship • Selective Pathology
2015 - 2016
New York Medical College
nymc.edu
Medical School
Until 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 88305Pathology examination of tissue using a microscope, intermediate complexity | 621 | 1,012 |
| 2 | 88304Pathology examination of tissue using a microscope, moderately low complexity | 160 | 165 |
| 3 | 88311Preparation of tissue for examination by removing any calcium present | 127 | 132 |
| 4 | 88342Tissue or cell analysis by immunologic technique | 101 | 127 |
| 5 | 88307Pathology examination of tissue using a microscope, moderately high complexity | 88 | 163 |
Authors: Vasquez, Ivan, Tan, Nhi, Boonyasampant, Mark, Koppitch, Kari A, Lansman, Jeffry B
Journal: J Physiol
Publication Date: 2012-09-10
Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab